Inhibitors of MEK1/2 are currently used for therapy of BRAF mutated as well as Neurofibromatosis type 1 (NF1) mutated, KRAS and NRAS mutated tumors including treatment of RASopathies (Fig. 1). Here, MAP2K1 is linked to RASopathy.